Targeted Oncology· @TargetedOnc · X·· 22 小时前评分70
正文 · 原文
For my breast oncology colleagues:
Does KEYNOTE-B49 change your practice?
Would you consider pembrolizumab + chemotherapy in selected CPS ≥10 patients, or wait for stronger evidence of clinical benefit?
How does it fit alongside modern targeted therapies and ADCs?
#ESMO26
52 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Targeted Oncology · x.com